Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria
Antimicrobial Agents and Chemotherapy, Volume 49, No. 9, Year 2005
Notification
URL copied to clipboard!
Description
Fosmidomycin is effective against malaria, but it needs to be given for ≥4 days when used alone. We conducted a study of 50 children with Plasmodium falciparum malaria to evaluate the safety and efficacy of consecutively shortened regimens of artesunate-fosmidomycin (1 to 2 mg/kg of body weight and 30 mg/kg of body weight, respectively; doses given every 12 hours). All dosing regimens were well tolerated. Artesunate-fosmidomycin acted rapidly, resulting in consolidated geometric mean parasite and fever clearance times of 24 h and 15 h, respectively. Treatment regimens of ≥2 days led to cure ratios of 100% by day 14 (39/39; 95% confidence interval [95% CI], 91% to 100%). Most importantly, the 3-day regimen achieved 100% cure on day 28 (10/10; 95% CI, 69% to 100%). Treatment with artesunate-fosmidomycin was associated with transient grade I or II neutropenia (absolute neutrophil counts of 750 to 1,200/μl and 400 to 749/μl, respectively) in six or two patients, respectively. Artesunate-fosmidomycin demonstrates the feasibility and potential value of short-course artemisinin-based combination chemotherapy with rapidly eliminated combination partners. Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Authors & Co-Authors
Borrmann, Steffen
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Germany, Tubingen
Eberhard Karls Universität Tübingen
Kenya, Nairobi
Wellcome Trust Research Laboratories Nairobi
Adégnika, Ayôla Akim
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Germany, Tubingen
Eberhard Karls Universität Tübingen
Moussavou, Félicien
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Gabon, Libreville
Faculte de Medecine et Des Sciences de la Sante
Oyakhirome, Sunny
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Esser, Gilbert
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Germany, Tubingen
Eberhard Karls Universität Tübingen
Matsiégui, Pierre Blaise
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Germany, Tubingen
Eberhard Karls Universität Tübingen
Ramharter, Michael
Austria, Vienna
Medizinische Universität Wien
Lundgren, Ingrid
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
United States, Rochester
Mayo Medical School
Kombila, Maryvonne Y.
Gabon, Libreville
Faculte de Medecine et Des Sciences de la Sante
Issifou, Saadou
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Germany, Tubingen
Eberhard Karls Universität Tübingen
Hutchinson, David B.A.
Germany, Hamburg
Jomaa Pharma Gmbh
Wiesner, Jochen
Germany, Giessen
Justus-liebig-universität Gießen
Jomaa, Hassan
Germany, Giessen
Justus-liebig-universität Gießen
Kremsner, Peter G.
Gabon, Lambarene
Unité de Recherche Médicale, Albert Schweitzer Hospital
Germany, Tubingen
Eberhard Karls Universität Tübingen
Germany, Tubingen
Institute of Tropical Medicine
Statistics
Citations: 70
Authors: 14
Affiliations: 9
Identifiers
Doi:
10.1128/AAC.49.9.3749-3754.2005
ISSN:
00664804
Research Areas
Cancer
Infectious Diseases
Maternal And Child Health